# Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria

> **NCT04853992** · PHASE2 · COMPLETED · sponsor: **JW Pharmaceutical** · enrollment: 20 (actual)

## Conditions studied

- Cholinergic Urticaria

## Interventions

- **DRUG:** LEO 152020
- **DRUG:** LEO 152020 placebo

## Key facts

- **NCT ID:** NCT04853992
- **Lead sponsor:** JW Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-10
- **Primary completion:** 2022-07-08
- **Final completion:** 2022-07-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04853992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04853992, "Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04853992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*